BR9904773A - Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém. - Google Patents
Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém.Info
- Publication number
- BR9904773A BR9904773A BR9904773A BR9904773A BR9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A
- Authority
- BR
- Brazil
- Prior art keywords
- sialic acid
- oligosaccharide
- galactose
- glucose
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
CONHECENDO O OLIGOSSACARìDEO DE áCIDO SIáLICO N-GLS E COMPOSIçãO QUE O CONTéM".<D> A presente invenção refere-se ao campo de imunologia e medicina humana, particularmente com a geração e a seleção de um anticorpo monoclonal (Mab) que reconhece a seq³ência de oligossacarídeo de ácido siálico N-glicolilado com galactose-glicose, presente em tumores malignos. Um dos objetivos desta invenção é proporcionar um Mab do tipo IgG1, que tem a característica de reconhecer, com alta especificidade, a seq³ência de oligossacarídeo de ácido siálico N-glicolilado com galactose-glicose, presente em tecidos malignos da mama, melanomas e tumores do fígado, estómago, cólon, reto e rins. Ele também tem a capacidade de produzir citólise direta das células tumorais contendo a seg³ência de oligossacarídeo de ácssim pode ser usado para a diagnose e tratamento dda presente invenção é proporcionar o hibridoma que produz o referido Mab, assim como a composição farmecêutica contendo-o, para o tratamento de doenças neoplásicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1998022A CU22731A1 (es) | 1998-02-05 | 1998-02-05 | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
PCT/CU1999/000001 WO1999040119A1 (es) | 1998-02-05 | 1999-02-05 | Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9904773A true BR9904773A (pt) | 2000-03-21 |
Family
ID=5459215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9904773A BR9904773A (pt) | 1998-02-05 | 1999-02-05 | Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém. |
Country Status (17)
Country | Link |
---|---|
US (1) | US6429295B1 (pt) |
EP (1) | EP0972782B1 (pt) |
JP (1) | JP4125383B2 (pt) |
CN (1) | CN1149224C (pt) |
AR (1) | AR013021A1 (pt) |
AT (1) | ATE250085T1 (pt) |
AU (1) | AU764632B2 (pt) |
BR (1) | BR9904773A (pt) |
CA (1) | CA2286288C (pt) |
CO (1) | CO4810341A1 (pt) |
CU (1) | CU22731A1 (pt) |
DE (1) | DE69911322T2 (pt) |
DK (1) | DK0972782T3 (pt) |
ES (1) | ES2209391T3 (pt) |
MX (1) | MXPA99009082A (pt) |
PT (1) | PT972782E (pt) |
WO (1) | WO1999040119A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1349567A4 (en) * | 2000-12-08 | 2005-10-12 | Childrens Memorial Hospital | COMPOSITIONS WITH GANGLIOSIDES FOR USE IN THE TREATMENT OF SKIN DISEASES |
CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US20040115204A1 (en) * | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
CA2510250A1 (en) * | 2002-12-20 | 2004-08-12 | Momenta Pharmaceuticals, Inc. | Glycan markers for diagnosing and monitoring disease |
CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
CU23297A1 (es) * | 2004-11-16 | 2008-07-24 | Ct De Inmunologa A Molecular | Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer |
CN101835319B (zh) | 2009-03-13 | 2014-05-07 | 奥斯兰姆有限公司 | 用于电子镇流器的外壳 |
DK2552959T3 (en) | 2010-03-26 | 2017-05-01 | Memorial Sloan Kettering Cancer Center | ANTIBODIES FOR MUC16 AND PROCEDURES FOR USE THEREOF |
US20120148559A1 (en) | 2010-12-01 | 2012-06-14 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
WO2012106368A2 (en) | 2011-01-31 | 2012-08-09 | The Regents Of The University Of California | Methods for inhibiting prostate cancer |
CU24070B1 (es) | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
CU24120B1 (es) | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
CN104651314B (zh) | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
US10722523B2 (en) | 2015-03-17 | 2020-07-28 | The Regents Of The University Of California | Chemoimmunotherapy for epithelial cancer |
BR112017019978A2 (pt) | 2015-03-17 | 2018-06-19 | Memorial Sloan Kettering Cancer Center | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo |
CN109721632B (zh) * | 2017-10-27 | 2023-10-31 | 齐鲁制药有限公司 | 一种高纯度神经节苷脂gm1及其制备方法 |
CU20210104A7 (es) | 2021-12-21 | 2023-07-12 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965198A (en) * | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
ATE175234T1 (de) * | 1990-07-10 | 1999-01-15 | Nippon Kokan Kk | Geflügelspezifischen immunglobulin g produzierende hybridomas |
CA2137638C (en) | 1993-12-09 | 1999-07-20 | Ana M. V. Lopez | Anti gangliosides monoclonal antibodies and their use in the specific active immunotherapy of malignant tumors |
-
1998
- 1998-02-05 CU CU1998022A patent/CU22731A1/es unknown
-
1999
- 1999-02-05 DE DE69911322T patent/DE69911322T2/de not_active Expired - Lifetime
- 1999-02-05 DK DK99903581T patent/DK0972782T3/da active
- 1999-02-05 AU AU24078/99A patent/AU764632B2/en not_active Expired
- 1999-02-05 CO CO99006716A patent/CO4810341A1/es unknown
- 1999-02-05 MX MXPA99009082A patent/MXPA99009082A/es not_active IP Right Cessation
- 1999-02-05 EP EP99903581A patent/EP0972782B1/en not_active Expired - Lifetime
- 1999-02-05 ES ES99903581T patent/ES2209391T3/es not_active Expired - Lifetime
- 1999-02-05 WO PCT/CU1999/000001 patent/WO1999040119A1/es active IP Right Grant
- 1999-02-05 CN CNB998002615A patent/CN1149224C/zh not_active Expired - Lifetime
- 1999-02-05 BR BR9904773A patent/BR9904773A/pt not_active IP Right Cessation
- 1999-02-05 JP JP53982099A patent/JP4125383B2/ja not_active Expired - Lifetime
- 1999-02-05 AR ARP990100494A patent/AR013021A1/es active IP Right Grant
- 1999-02-05 US US09/402,521 patent/US6429295B1/en not_active Expired - Lifetime
- 1999-02-05 PT PT99903581T patent/PT972782E/pt unknown
- 1999-02-05 CA CA2286288A patent/CA2286288C/en not_active Expired - Lifetime
- 1999-02-05 AT AT99903581T patent/ATE250085T1/de active
Also Published As
Publication number | Publication date |
---|---|
DE69911322T2 (de) | 2004-07-01 |
PT972782E (pt) | 2004-02-27 |
DK0972782T3 (da) | 2004-02-02 |
CA2286288A1 (en) | 1999-08-12 |
US6429295B1 (en) | 2002-08-06 |
CU22731A1 (es) | 2002-02-28 |
CO4810341A1 (es) | 1999-06-30 |
DE69911322D1 (de) | 2003-10-23 |
EP0972782B1 (en) | 2003-09-17 |
ATE250085T1 (de) | 2003-10-15 |
AU764632B2 (en) | 2003-08-28 |
EP0972782A1 (en) | 2000-01-19 |
JP4125383B2 (ja) | 2008-07-30 |
AU2407899A (en) | 1999-08-23 |
AR013021A1 (es) | 2000-11-22 |
MXPA99009082A (es) | 2002-04-24 |
CN1256696A (zh) | 2000-06-14 |
WO1999040119A1 (es) | 1999-08-12 |
CN1149224C (zh) | 2004-05-12 |
JP2001509684A (ja) | 2001-07-24 |
CA2286288C (en) | 2010-09-28 |
WO1999040119A9 (es) | 2000-07-06 |
ES2209391T3 (es) | 2004-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9904773A (pt) | Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém. | |
Lindner et al. | Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein | |
Visser et al. | Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol | |
Shreve et al. | Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants | |
Van Nostrand | The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer | |
Wållberg et al. | Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties | |
Colcher et al. | Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma | |
Rainsbury et al. | Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111 | |
Collins et al. | Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies | |
Jacobson et al. | PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer | |
RU2161042C2 (ru) | Обнаружение и лечение рака | |
Stein et al. | Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors | |
Zettlitz et al. | A dual-modality linker enables site-specific conjugation of antibody fragments for 18F-immuno-PET and fluorescence imaging | |
RU2016124229A (ru) | Полипептиды антител и их применения | |
Tang et al. | A radiopharmaceutical [89Zr] Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo | |
Davies et al. | Radionuclide imaging of ovarian tumours with 123I‐labelled monoclonal antibody (NDOG2) directed against placental alkaline phosphatase | |
Lamki et al. | Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen | |
BR112022019853A2 (pt) | Imunoconjugado que se liga especificamente a eno-1, composição para diagnóstico ou imagem de células ou de um tecido que expressa eno-1, composição farmacêutica para uso no tratamento de uma doença inflamatória, método para tratar uma doença inflamatória, e uso do imunoconjugado | |
Powe et al. | Labeling monoclonal antibodies and F (ab') 2 fragments with (111In) indium using cyclic DTPA anhydride and their in vivo behavior in mice bearing human tumor xenografts | |
Kumar et al. | 64Cu-labeled peptide for PET of breast carcinomas expressing the thomsen-friedenreich carbohydrate antigen | |
Andersson et al. | Bile salt malabsorption in the radiation syndrome | |
Meyer et al. | CT evaluation of locally advanced carcinoma of the distal colon and rectum | |
Bamias et al. | Intravesical administration of indium‐111‐labelled hmfg2 monoclonal antibody in superficial bladder carcinomas | |
SHEPHERD et al. | Tumour‐associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer | |
Suissa et al. | Plasmacytoma of lymph nodes: a case report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/30 (2006.01), A61K 38/00 (2006.0 |